Following receipt of the Pfizer COVID-19 vaccine on Monday morning, MD Anderson’s Pharmacy, Infection Control, Employee Health and clinical and facilities experts re-reviewed protocols and procedures, and an initial vaccination clinic simulation was completed. Based on those successful efforts along with a manager briefing and employee town hall, positive feedback from managers about employee engagement and swift uptake of appointment...
Mariana Chavez Mac Gregor, M.D., M.Sc., associate professor in Health Services Research with a joint appointment in Breast Medical Oncology...
The University of Texas MD Anderson Cancer Center is prepared to accept, store and distribute the Pfizer COVID-19 vaccine following the Food...
ABSTRACT 464
A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative...
ABSTRACT 405
A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19...
ABSTRACT 167
A phase I/II study led by researchers from The University of Texas MD Anderson Cancer Center found IMGN632, a novel CD123...
The University of Texas MD Anderson Cancer Center today named Welela Tereffe, M.D., as chief medical executive (CME). Recognized as a patient-centered...
In recognition of their achievements in advancing cancer research, five faculty members from The University of Texas MD Anderson ...
Researchers at The University of Texas MD Anderson Cancer Center have developed a novel targeted therapy, called POMHEX, which blocks critical...
The University of Texas MD Anderson Cancer Center and more than 100 of the nation’s top health care systems, representing thousands of hospitals...
The North Texas A Conversation With a Living Legend® raised $1 million this week in a virtual version of the signature fundraising event benefiting...
The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced a multi-year strategic collaboration designed...
Sherry Adkins is the recipient of the 2020 Brown Foundation Award for Excellence in Oncology Nursing at The University of Texas MD Anderson...
The University of Texas MD Anderson Cancer Center has named 10 early-career faculty members to the 2020 class of Andrew Sabin Family Fellows...
ABSTRACTS 277, 368, 420
Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight...
Through large-scale profiling of protein changes in response to drug treatments in cancer cell lines, researchers at The University of Texas...
A new collaboration combining cancer research with advanced computing and computational modeling techniques received strong engagement and...
Researchers from The University of Texas MD Anderson Cancer Center have conducted the first randomized clinical trial comparing stereotactic...
HOUSTON ― The University of Texas MD Anderson Cancer Center will host the fifth annual Boot Walk to End Cancer® virtually on Saturday, Nov...
The Focus Fund GP, LLC, in partnership with The University of Texas MD Anderson Cancer Center, has launched Cancer Focus Fund, LP, an oncology-focused...
Cancer remains one of the leading causes of death worldwide. While advances in cancer diagnoses and treatments are promising, more is needed...
The University of Texas MD Anderson Cancer Center and Allogene Therapeutics, Inc. today announced a strategic five-year collaboration agreement...
The University of Texas MD Anderson Cancer Center today announced achievement of its fifth consecutive Magnet designation, the highest distinction...
Neoadjuvant, or pre-surgical, combination treatment with the immune checkpoint inhibitors tremelimumab (anti-CTLA-4) and durvalumab (anti-PD...
Researchers at The University of Texas MD Anderson Cancer Center have identified molecular and cellular characteristics of anti-CD19...
A new study from researchers at The University of Texas MD Anderson Cancer Center has discovered that mutations found in cancers do not accumulate...
A new data analysis tool developed by researchers at The University of Texas MD Anderson Cancer Center incorporates a user-friendly,...
The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical Co., Ltd., today announced a three-year strategic collaboration...
The University of Texas MD Anderson Cancer Center has awarded Monica Johnson, M.H.A., C.P.X.P., the Julie and Ben Rogers Award for Excellence...
ABSTRACT: 1257O
In a Phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRASG12C inhibitor...
New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc...
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab...
The University of Texas MD Anderson Cancer Center and Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co....
The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic collaboration to study investigational...
The University of Texas MD Anderson Cancer Center Board of Visitors (BOV) has named 15 new members and bestowed its highest honor of Life...
For patients with non-small cell lung cancers (NSCLC) marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and...
The University of Texas MD Anderson Cancer Center today was awarded nearly $9 million from the Cancer Prevention and Research Institute...
In a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, the combination of dabrafenib, a BRAF inhibitor...
Two different types of detectable antibody responses in SARS-CoV-2 (COVID-19) tell very different stories and may indicate ways to enhance...
A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients...
The University of Texas MD Anderson Cancer Center is committed to safely providing patient care and cancer screenings throughout the novel...
According to researchers from The University of Texas MD Anderson Cancer Center, the implementation of social distancing policies corresponded...
The University of Texas MD Anderson Cancer Center is honored to rank No. 1 in cancer care in the U.S. News & World Report’s 2020...
The University of Texas MD Anderson Cancer Center and Sanofi today announced a five-year strategic collaboration to accelerate the development...
The University of Texas MD Anderson Cancer Center and two institutions at The University of Texas at Austin – the Oden Institute for Computational...
Public Notice
MAGNET RECOGNITION PROGRAM® — SITE VISIT
· The University of Texas...
In the first study to look at objective measures of sedentary behavior and cancer mortality, researchers from The University of Texas MD Anderson...
In patients with metastatic bladder cancer, a novel combination of biomarkers from baseline tumor tissues was predictive of improved clinical...
The University of Texas MD Anderson Cancer Center and Royal Philips today announced a collaboration to provide oncologists with evidence-based...
The University of Texas MD Anderson Cancer Center and Rakuten Medical, Inc. today announced a strategic alliance collaboration agreement to...
At MD Anderson, we are filled with anguish and deep sorrow over the senseless acts of racism and violence in our country and the tragic death...
ABSTRACT: #102
The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4...
ABSTRACT: #109
The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety...
Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate...
ABSTRACT: #5003
In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with...
ABSTRACT: #7500
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective...
The University of Texas MD Anderson Cancer Center and Innovent Biologics, Inc. today announced a strategic collaboration agreement to co-develop...
Patients with advanced BRCA-mutated breast cancer found no overall survival benefit with talazoparib
ABSTRACT: CTO71
New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center...
ABSTRACT: DDT01-03
In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers...
Guillermina Lozano, Ph.D., chair of Genetics at The University of Texas MD Anderson Cancer Center, has been elected as...
The University of Texas MD Anderson Cancer Center is committed to keeping our patients, our workforce members and our community safe throughout...
A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma...
Although metastatic castration-resistant prostate cancer (mCRPC) typically has limited response to immunotherapy, a subset of patients with...
New findings from researchers at The University of Texas MD Anderson Cancer Center about how some cancer cells become “addicted” to glucose...
Treating T cells harvested from a patient with a combination of an epigenetic drug and a cytokine while expanding the cells in the lab re-programs...
Medical experts have always known myelin, the protective coating of nerve cells, to be metabolically inert. A study led by The University...
A study conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated acceptable toxicity and anti-tumor activity...
The University of Texas MD Anderson Cancer Center is preparing to return to normal operations on Monday morning, March 2, after operating...
A study at The University of Texas MD Anderson Cancer Center discovered a novel therapeutic vulnerability for patients who have tumors caused...
Comprehensive profiling of tumor samples taken from patients with osteosarcoma shows that multiple factors contribute to the traditionally...
The University of Texas MD Anderson Cancer Center today announced a strategic research collaboration with Denali Therapeutics Inc. to develop...
The University of Texas MD Anderson Cancer Center today was awarded more than $20 million from the Cancer Prevention and Research Institute...
The University of Texas MD Anderson Cancer Center today announced the Houston Dash will join the institution's efforts toward one goal...
Loss of an important tumor-suppressing gene allows head and neck cancer to spin off signals to nearby nerves, changing their function and...
According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric...
A study led by The University of Texas MD Anderson Cancer Center furthered understanding about mitochondria, the cell components known as...
The University of Texas MD Anderson Cancer Center honors World Cancer Day, Feb. 4, as the campaign celebrates 20 years of bringing awareness...
A study at The University of Texas MD Anderson Cancer Center showed that circulating tumor cells (CTCs), a form of liquid biopsy, was independently...
In the first comparative clinical trial of lung cancer screening decision aid versus standard educational information, researchers from The...
The University of Texas MD Anderson Cancer Center has announced that the Texas Health and Human Services Commission, on behalf of the Centers...
The University of Texas MD Anderson Cancer Center today named Craig Owen as its chief information officer. Owen has served the institution...
The likelihood of a patient responding to immune checkpoint blockade may depend on B cells in the tumor, located within specialized immune-cell...
A study at The University of Texas MD Anderson Cancer Center demonstrated a potential new approach to treating two of the most common subtypes...